View Older Stories View More Recent Stories

Oct 27, 2020 08:00AM Esperion to Participate in Three Upcoming Virtual Investor Conferences
Oct 19, 2020 08:00AM Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
Oct 19, 2020 08:00AM Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
Oct 7, 2020 08:00AM NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
Oct 7, 2020 08:00AM NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
Sep 28, 2020 04:07PM Esperion Therapeutics (ESPR) Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL Tablets and Increase Awareness of Bad Cholesterol
Sep 28, 2020 04:06PM Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
Sep 28, 2020 04:06PM Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
Sep 2, 2020 08:41AM Esperion to Participate in Two Upcoming Virtual Investor Conferences
Sep 2, 2020 08:41AM Esperion to Participate in Two Upcoming Virtual Investor Conferences
Aug 26, 2020 09:07AM Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
Aug 26, 2020 09:07AM Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
Aug 21, 2020 04:05PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 21, 2020 04:05PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 10, 2020 04:04PM Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
Aug 10, 2020 04:04PM Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
Aug 3, 2020 07:26AM Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
Aug 3, 2020 07:26AM Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
Jul 1, 2020 11:14AM Esperion Therapeutics (ESPR) Announces Publication in JAMA Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL Tablets
Jul 1, 2020 11:12AM Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bem
Jul 1, 2020 11:12AM Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bem
Jun 15, 2020 05:57AM Esperion Therapeutics (ESPR) Presents Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL (Bempedoic Acid) Tablets
Jun 14, 2020 09:30AM Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessi
Jun 14, 2020 09:30AM Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessi
Jun 12, 2020 07:21AM Esperion Therapeutics (ESPR) Reports ICER Confirms NEXLETOL Tablets to be Included in Assessment of Non-Statin Medicines for Hypercholesterolemia
Jun 12, 2020 07:19AM Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
Jun 12, 2020 07:18AM Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
Jun 8, 2020 08:00AM Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
Jun 8, 2020 08:00AM Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
Jun 4, 2020 07:10AM Esperion Therapeutics (ESPR) Highlights Commercial Availability of NEXLIZET (bempedoic acid and ezetimibe) Tablets
Jun 4, 2020 07:00AM Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
Jun 4, 2020 07:00AM Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
May 27, 2020 08:00AM Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
May 27, 2020 08:00AM Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
May 15, 2020 06:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2020 06:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 7, 2020 08:00AM Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
May 7, 2020 08:00AM Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
May 6, 2020 04:05PM Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
May 6, 2020 04:05PM Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
Apr 30, 2020 08:00AM Esperion to Report First Quarter 2020 Financial Results May 6, 2020
Apr 30, 2020 08:00AM Esperion to Report First Quarter 2020 Financial Results May 6, 2020
Apr 20, 2020 07:05AM Esperion Therapeutics (ESPR), Otsuka Pharma Report Collaboration on Development and Commercialization of NEXLETOL & NEXLIZET Tablets in Japan
Apr 20, 2020 07:00AM Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
Apr 20, 2020 07:00AM Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
Apr 9, 2020 08:00AM Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
Apr 9, 2020 08:00AM Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
Apr 6, 2020 07:10AM Esperion Therapeutics (ESPR) Announces EC Approval of NUSTENDI Tablet for Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Apr 6, 2020 07:05AM Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Apr 6, 2020 07:05AM Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
View More Recent Stories View Older Stories